Streetbeat News

Price Targets

HOLX

Mizuho analyst Anthony Petrone maintains an Outperform rating on Hologic and raises the price target from $85 to $90.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:27 pm

LIFE

aTyr Pharma shares rose after Wells Fargo initiated coverage with an Overweight rating and set a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:26 pm

EQT

Mizuho analyst Nitin Kumar has maintained a Neutral rating on EQT Corporation (NYSE:EQT) while lowering the price target from $43 to $41.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:23 pm

LNT

Mizuho analyst Anthony Crowdell maintains a Neutral rating on Alliant Energy (NASDAQ:LNT) and raises the price target from $52 to $61.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:20 pm

AIN

TD Cowen analyst Gautam Khanna maintains a Buy rating on Albany Intl (NYSE:AIN) but lowers the price target from $95 to $81.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:15 pm

AXSM

RBC Capital has maintained its 'Outperform' rating on Axsome Therapeutics and slightly raised the price target from $130 to $131.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:08 pm

SAGE

Sage Therapeutics (NASDAQ:SAGE) has been evaluated by 13 analysts, showing a mix of bullish and bearish perspectives. The average 12-month price target is $17.38, a 21.53% decrease from the previous target. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Sage Therapeutics is a clinical-stage biopharmaceutical company focusing on brain health medicines, with significant revenue growth but challenges in asset utilization.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:00 pm

HROW

Lake Street analyst Brooks O'Neil has maintained a Buy rating on Harrow (NASDAQ:HROW) and raised the price target from $45 to $55.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:00 pm

GPN

Analysts have provided mixed ratings for Global Payments (NYSE:GPN) over the past three months, with a decrease in the average 12-month price target from $147.72 to $140.33. Recent actions by analysts include several downgrades in price targets, reflecting a cautious outlook. Despite positive revenue growth, Global Payments faces challenges in profitability and financial performance compared to industry averages.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:00 pm

VRCA

RBC Capital analyst Gregory Renza maintains an Outperform rating on Verrica Pharmaceuticals but lowers the price target from $13 to $11.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:56 pm